fda warning letters compounded tirzepatide 2024 2025 Beyond the Headlines: to GLP-1 Compounders US FDA Warning Letters: Considerations

This is especially important for patients reporting severe appetite suppression or fatigue

These effects are expected to be extra-hepatic and a consequence of attenuation of hyperglycemia

Patients who have had mixed or unclear GLP-1 responses in the past, or who want biomarker context before starting treatment, may benefit from PlexusDx's genetic-pathway option

Notably, the type and dose of statins used in the statin YES stratum before the enrolment were homogeneous between study groups, with the sole exception of rosuvastatin, which was more frequently used in the ALC group than in the placebo group [13 patients vs 4 patients ( P = 0.0001), respectively]